Shingrix in Renal Transplant Recipients

Inclusion Criteria:

• On the waiting list at the participating institutions for renal transplantation withanticipated transplantation to occur at > 3 months to 16 months after listing.

• Female subjects of non-childbearing potential (tubal ligation,hysterectomy,ovariectomy or post-menopausal

• Female subjects of childbearing potential who have practiced adequate contraceptionfor 30 days prior to vaccination, have a negative pregnancy test on day ofvaccination, and have agreed to continue adequate contraception during the entiretreatment period and for 2 months after completion of the vaccine series

Exclusion Criteria:

• Therapy in the pre-transplant period that in the opinion of the investigator isimmune suppressive

• Herpes Zoster in prior 3 years

• Herpes zoster vaccine or varicella vaccine within 3 years of study entry

• Any positive cPRA score prior to enrollment

• Acute illness at the time of vaccination which in the opinion of the investigatorwill alter immune response

• Any other active immunosuppressive or immunodeficient condition resulting fromdisease (e.g. malignancy, HIV, or a medical therapy).

• Allergy to any of the components of Shingrix

• No investigational drugs from 30 days before enrollment or planned during the study.

• No non-live vaccines within the 2 weeks prior to any dose of Shingrix or until 30days after any dose of Shingrix. No live virus vaccines within 4 weeks prior to anydose of Shingrix or until 30 days after any dose

• Pregnant or lactating female

• Multi-organ transplantation

• Travel time from study site that is more than 2 hours for visit or transport offresh blood samples